Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Polaryx Therapeutics, Inc. - Common Stock (NQ:PLYX)

1.990 -0.050 (-2.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,098
Open 2.050
Bid (Size) 1.990 (100)
Ask (Size) 2.100 (1,500)
Prev. Close 2.040
Today's Range 1.981 - 2.072
52wk Range 1.850 - 48.91
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-94.3%
-94.3%
1 Month
-9.1%
-9.1%
3 Month
-21.0%
-21.0%
6 Month
-28.7%
-28.7%
1 Year
-94.3%
-94.3%

More News

Read More
News headline image
Why Polaryx Therapeutics Stock Is Surging On Thursday? ↗
Via Benzinga
News headline image
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
Tuesday's session: top gainers and losers ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
Via Stocktwits
Topics ETFs
News headline image
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's Going On With Polaryx Therapeutics Stock Wednesday? ↗
Via Benzinga
News headline image
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans ↗
Via Benzinga
News headline image
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Welcomes New Members of the Board of Directors
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
From Polaryx Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Polaryx Therapeutics, Inc. - Common Stock publicly traded?
Yes, Polaryx Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Polaryx Therapeutics, Inc. - Common Stock trade on?
Polaryx Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Polaryx Therapeutics, Inc. - Common Stock?
The ticker symbol for Polaryx Therapeutics, Inc. - Common Stock is PLYX on the Nasdaq Stock Market
What is the current price of Polaryx Therapeutics, Inc. - Common Stock?
The current price of Polaryx Therapeutics, Inc. - Common Stock is 1.990
When was Polaryx Therapeutics, Inc. - Common Stock last traded?
The last trade of Polaryx Therapeutics, Inc. - Common Stock was at 09/03/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>